Skip to main content
Log in

Assessing the risks, benefits and costs of stroke prevention in AF

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCE

  1. Hughes M, Lip GYH, Guideline Development Group for the NICE national clinical guideline for management of atrial fibrillation in primary and secondary care.Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thrombosis and Haemostasis 99: 295-304, No. 2, Feb 2008

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Assessing the risks, benefits and costs of stroke prevention in AF. Pharmacoecon. Outcomes News 549, 4 (2008). https://doi.org/10.2165/00151234-200805490-00009

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200805490-00009

Keywords

Navigation